Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced it has completed a $47 million extension of its Series A financing. This brings the total Series A funding raised by Ambys to $107 million. Ambys is developing an entirely new approach to treating severe liver disease. The company's liver-cell production processes can produce, at scale, high-quality liver cells that function in vivo as normal healthy liver cells. The company is advancing multiple preclinical programs. The proceeds from this financing will enable the continued expansion of Ambys's proprietary liver cell therapy production capabilities and the advancement of the company's lead program, AMI-918, through pre-IND activities. Third Rock Ventures led the financing with participation from Takeda, Schroders Capital, Laurion Capital, Smilegate Investment, and Alexandria Venture Investments, among others.

Ambys Medicines is focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease. Ambys' proprietary cell therapy platform potentially solves the supply constraints that have hindered progress, catalyzing the field and fundamentally transforming the approach to treating severe liver disease. Our lead program, AMI-918, and future engineered hepatocyte cell therapies are being developed across the spectrum of severe liver disease, including those of acquired and genetic origins.